Transcatheter Mitral Valve Implantation (TMVI)

The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach that is currently undergoing first-in-man trials. Below is a link to the paper with the latest evidence on the device and a link to the news release.

Bapat et al. 2014 Eurointervention

Edwards News Release

X0000_Edwards_Fortis transcatheter Mitral valve copy_0

About The Author

SHDA is supported by

Recent Tweets

Subscribe

Upcoming Meetings

july

28julAll DaySHDA Aortic Valve Symposium 2018SHDA AVS 2018

august

02augAll Day05Cardiac Society of Australia & New Zealand (CSANZ) 66th Annual Scientific MeetingCSANZ 2018

03augAll Day05Australia & New Zealand Endovascular Therapies (ANZET) Meeting 2018ANZET 2018

25augAll Day29European Society of Cardiology (ESC) Congress 2018ESC 2018

X